Parkinson’s Disease: Independent Evidence on Treatment & Funding

Table of contents

• Evidence summary
• What Parkinson's disease is
• Symptoms and red flags
• How it is diagnosed
• Causes and risk factors
• Treatments that work and treatments that do not
• Medicines: levodopa, agonists and MAO-B inhibitors
• Deep brain stimulation
• Exercise and therapies
• Non-motor symptoms: constipation, sleep and mood
• Supplements and lifestyle claims, graded
• Risks and side effects
• Who to see
• Follow the money: who funds Parkinson's research
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator or government body; 2 = academic or Cochrane team with no declared commercial funding for the work; 3 = independent authors with declared industry ties, or work that relies on a manufacturer's hardware or supplies; 4 = manufacturer-funded or manufacturer-sponsored. Credibility runs from A (highest) to D. For a condition rather than a product, we treat patient-advocacy funders with an interest in drug development as tier 3. Our sources cluster heavily in the US, UK and Germany, with one Dutch trial, so the picture reflects the research priorities of wealthy health systems.

What Parkinson's disease is

Parkinson's disease is a slowly progressive condition in which nerve cells in a brain area called the substantia nigra are lost, reducing dopamine, a chemical that helps control movement (NHS). It is not curable, but treatments can reduce the main symptoms. The NHS says most people start to develop symptoms after 50 and men are slightly more likely than women to be affected.

Numbers matter for planning care. The Global Burden of Disease analysis estimated 6.1 million people (95% uncertainty interval 5.0 to 7.3 million) lived with Parkinson's disease worldwide in 2016, up from 2.5 million in 1990, and 211,296 deaths were attributed to it (Lancet Neurol 2018). Part of the rise is ageing: age-standardised prevalence rose by 21.7% (95% UI 18.1% to 25.3%), compared with 74.3% for crude prevalence. The age-standardised male-to-female ratio was 1.40. These are modelled estimates, funded by the Gates Foundation (full text).

Parkinson's disease has to be told apart from other parkinsonian syndromes. NICE therefore tells doctors to review the diagnosis at regular intervals and to reconsider it if atypical features develop (NG71, 1.2.5). It is also separate from the heart rhythm condition with a similar name, which we cover in Wolff-Parkinson-White syndrome.

Symptoms and red flags

The main symptoms are involuntary shaking (tremor), slow movement and stiff, inflexible muscles. Other symptoms include depression, anxiety, balance problems, loss of sense of smell, insomnia and memory problems (NHS). NICE tells doctors to suspect the disease in people with tremor, stiffness, slowness, balance problems or gait disorders, and to refer quickly and untreated to a specialist (NG71, 1.2.1 and 1.2.2).

How it is diagnosed

Parkinson's disease is diagnosed clinically, using the UK Parkinson's Disease Society Brain Bank criteria (NG71, 1.2.3). NICE does not recommend structural MRI to diagnose it, or PET, magnetic resonance volumetry or spectroscopy, acute levodopa or apomorphine challenge tests, or objective smell testing outside trials (NG71, 1.2.8 to 1.2.14). The one scan NICE does support is 123I-FP-CIT SPECT, often called a DaTscan, which can be considered for people with tremor when essential tremor cannot be told apart from parkinsonism on examination (NG71, 1.2.6).

NICE adds that people should see a doctor with Parkinson's expertise at regular intervals, every 6 to 12 months, to review the diagnosis, and that people who drive should inform the Driver and Vehicle Licensing Agency (DVLA) and their insurer (NG71, 1.2.5 and 1.1.7). Quick specialist referral and regular review matter because the diagnosis is made clinically.

Causes and risk factors

The NHS says the exact cause of the nerve cell loss is unclear, and experts think it is a mix of genetic and environmental factors (NHS). Most people start to have symptoms after 50, and men are slightly more likely to develop it.

Pesticides and the environment

The evidence on pesticides is observational, so it shows association rather than proof. In a case-control study nested in a cohort of 84,740 mostly farmer pesticide applicators and spouses in Iowa and North Carolina, 110 people with Parkinson's and 358 controls were analysed. Ever having used paraquat was linked with an odds ratio of 2.5 (95% CI 1.4 to 4.7) and rotenone with 2.5 (1.3 to 4.7) (Tanner et al. 2011). The authors listed their own limits: most participants used many pesticides, exposure was recalled rather than measured, and exposed numbers were small.

A meta-analysis of 104 studies by Italian researchers found that exposure to weed and bug killers and solvents was associated with a 33% to 80% higher risk, and that in controlled studies paraquat, maneb and mancozeb were each associated with about double the risk (AAN press release on Cereda and Pezzoli 2013). We read that work only through the American Academy of Neurology's press release, so we have not checked its pooled estimates against the paper.

Causation is contested in court as well as in journals. As of mid-April 2025, more than 5,800 active lawsuits were pending in a US federal multidistrict litigation alleging that paraquat causes Parkinson's disease. The maker, Syngenta, said it stands by the safety of paraquat, said that no peer-reviewed analysis had concluded it causes the disease, and said a settlement agreement did not imply wrongdoing (The New Lede, April 2025). We return to who is who in the money section.

Genes

The Michael J. Fox Foundation describes a gene called LRRK2 as the largest known genetic contributor to the disease (Foundation announcement). That is the foundation's own description, and we did not find an independent source to check it.

Treatments that work and treatments that do not

Medicines: levodopa, dopamine agonists and MAO-B inhibitors

What NICE says to offer first

NICE says to offer levodopa to people in the early stages whose motor symptoms affect their quality of life, and to consider a choice of dopamine agonists, levodopa or MAO-B inhibitors for people whose symptoms do not (NG71, 1.3.5 and 1.3.6). Its comparison table states that levodopa gives more improvement in motor symptoms and daily activities but more motor complications, while dopamine agonists and MAO-B inhibitors give less improvement and fewer motor complications. Dopamine agonists carry more of the specified adverse events: excessive sleepiness, hallucinations and impulse control disorders (NG71, Table 1). NICE says not to offer ergot-derived dopamine agonists first-line (NG71, 1.3.7).

PD MED: the trial that tested that choice

PD MED randomised 1,620 newly diagnosed people to levodopa, a dopamine agonist or an MAO-B inhibitor between 2000 and 2009, with a median follow-up of 3 years and up to 7 years. The main outcome was the mobility dimension of the PDQ-39 questionnaire. Levodopa scored 1.8 points better than the two levodopa-sparing strategies combined (95% CI 0.5 to 3.0; P=0.005). MAO-B inhibitors scored 1.4 points better than agonists (95% CI 0.0 to 2.9; P=0.05). On the EQ-5D utility score levodopa was 0.03 better (95% CI 0.01 to 0.05). Death, dementia and admission to institutional care did not differ significantly. Side effects led 28% of agonist users, 23% of MAO-B inhibitor users and 2% of levodopa users to stop (PD MED, Lancet 2014). The effects are small, and the people and doctors knew which treatment was given.

Does starting levodopa early do harm or good in the long run?

In LEAP, 445 people with early disease took levodopa for 80 weeks or placebo for 40 weeks followed by levodopa for 40 weeks. The UPDRS difference at 80 weeks was 1.0 point (95% CI -1.5 to 3.5; P=0.44), below the 4 points thought clinically important. NIHR's summary notes better symptom control in the early group during the first 40 weeks, similar side effects, and that 87 people in the delayed group started levodopa before week 40 because of symptoms (LEAP; NIHR Evidence). At 5 years, dyskinesia (involuntary movements) was seen in 46 of 160 early-start and 62 of 161 delayed-start participants (P=0.06) (Movement Disorders 2024). The message is that the timing of levodopa can follow symptoms.

Add-on medicines

For people with dyskinesia or motor fluctuations despite optimal levodopa, NICE says to offer a choice of dopamine agonists, MAO-B inhibitors or COMT inhibitors as an adjunct, to consider amantadine for dyskinesia, and not to offer anticholinergics to people with dyskinesia or motor fluctuations. It says to seek specialist advice before changing treatment (NG71, 1.3.9 to 1.3.14). Advanced options include apomorphine injection or infusion (NG71, 1.8.1).

Impulse control disorders

In the cross-sectional study of 3,090 treated people at 46 centres in the US and Canada, 13.6% had at least one impulse control disorder: compulsive buying 5.7%, gambling 5.0%, binge eating 4.3% and compulsive sexual behaviour 3.5%. Prevalence was 17.1% with an agonist versus 6.9% without (OR 2.72, 95% CI 2.08 to 3.54), and pramipexole and ropinirole had similar frequencies (Weintraub 2010). The registry lists Boehringer Ingelheim as the sponsor (ClinicalTrials.gov). Its direction of finding matches NICE, which recognises that these disorders can develop at any stage on any dopaminergic therapy, with higher risk from agonists, past impulsive behaviour, alcohol use and smoking (NG71, 1.4.1 and 1.4.2).

NICE's management pathway is to seek specialist advice, discuss gradually reducing any dopamine agonist while monitoring for withdrawal symptoms, and offer specialist cognitive behavioural therapy if changing medicines is not enough (NG71, 1.4.6 to 1.4.9). It also says doctors should record that they discussed these risks at the start of agonist treatment (NG71, 1.4.3). Stopping an agonist is a specialist decision, not something to do alone.

Deep brain stimulation

Deep brain stimulation (DBS) uses implanted electrodes and a pulse generator to stimulate a brain target; in the 2006 trial below it was the subthalamic nucleus. NICE says to offer people with advanced disease best medical therapy first, not to offer DBS when medicines control symptoms adequately, and to consider DBS for advanced disease that medicines do not adequately control (NG71, 1.8.1 to 1.8.3). NICE also notes that levodopa-carbidopa intestinal gel was then available through an NHS England clinical commissioning policy (NG71, 1.8.4).

The trial evidence

In the German trial of 156 people with advanced disease (78 pairs), neurostimulation produced greater improvements than medication alone over six months: mean 9.5 points on the PDQ-39 summary index (50 of 78 pairs, P=0.02) and 19.6 points on the UPDRS-III motor score without medication (55 of 78 pairs, P<0.001). Serious adverse events were more common with stimulation (13% versus 4%) (Deuschl et al. 2006). In EARLYSTIM, 251 people with early motor complications had a quality-of-life score that improved by 7.8 points with stimulation and worsened by 0.2 points with medical therapy alone, a difference of 8.0 points (P=0.002) (Schuepbach et al. 2013).

Who paid, and what that means

The 2006 trial was supported by a grant from the German Federal Ministry of Education and Research. The implants (a Medtronic electrode and pulse generator) came from Medtronic, many authors reported speaking fees from the company, several reported consulting fees or research grants, and one reported Medtronic stock options (NEJM 2006 full text). The EARLYSTIM abstract says it was funded by the German Ministry of Research "and others" (abstract); we could not open the full list. The conflicts are disclosed openly, which lets readers weigh them. They are a reason to look for replication from sources without device ties.

Exercise and therapies

NICE recommends considering early referral to a physiotherapist with Parkinson's experience for assessment and advice on physical activity, Parkinson's-specific physiotherapy for balance or motor problems, and considering the Alexander Technique for these problems (NG71, 1.7.2 to 1.7.4). It also recommends occupational therapy and speech and language therapy (NG71, 1.7.5 to 1.7.9). These are guideline recommendations; we did not review the underlying trials one by one.

What Cochrane found

The Cochrane network meta-analysis covered 156 randomised trials with 7,939 participants. Dance, gait, balance and functional training, multi-domain training and mind-body exercise showed clinically meaningful benefit for motor symptoms, and water-based exercise showed clinically meaningful benefit for quality of life. Estimates for strength, resistance and endurance training were similar but less precise. The authors found little evidence of much difference between exercise types and concluded that any structured exercise counts, so personal preference should guide choice. Participants were mostly aged 60 to 74 with mild to moderate disease, so results may not apply to advanced disease or cognitive impairment (Cochrane news item, January 2023). In numbers, dance had a mean motor-sign difference of -10.32 and water-based training a quality-of-life difference of -14.98; evidence on adverse events was very uncertain (abstract).

Can exercise change the disease?

The phase 2 SPARX trial randomised 128 people to high-intensity treadmill walking (80% to 85% of maximum heart rate), moderate intensity (60% to 65%) or usual care. At six months the UPDRS motor score had changed by +0.3 (95% CI -1.7 to 2.3) with high intensity, +2.0 (0.38 to 3.7) with moderate intensity and +3.2 (1.4 to 5.1) with usual care. Musculoskeletal problems occurred in 34.9% of the high-intensity group and 5.0% of usual care; two serious adverse events were judged unrelated to exercise. The authors declared no conflicts, and the abstract and results text give different P values for the main comparison (full text; abstract). A phase 3 successor (SPARX3) was registered to randomise 370 people with early, untreated disease and measure motor score at 12 months; we found no published results (protocol). Until then, exercise is a way to feel and move better, not a proven way to slow the disease. Our general guide to exercise and social support for mental health covers the mood side.

Non-motor symptoms: constipation, sleep and mood

Constipation

NICE NG71 contains no specific recommendation on constipation; we checked the full recommendation text. The research is thin. A meta-analysis of four randomised trials of probiotics (287 people) found 1.02 more bowel movements a week (95% CI 0.56 to 1.48) but with high inconsistency (heterogeneity 71.5%) and low certainty by GRADE (meta-analysis). We did not find a funding statement on the page we opened. For general options such as fibre, fluids and laxatives, see chronic constipation.

Sleep

NICE advises a detailed sleep history for daytime sleepiness before considering modafinil (not in pregnancy), identifying and managing restless legs and REM sleep behaviour disorder in people with sleep disturbance, and considering clonazepam or melatonin for REM sleep behaviour disorder once medicines have been reviewed. Both were off-label uses in 2017. For night-time stiffness (nocturnal akinesia) it suggests considering levodopa or oral dopamine agonists, then rotigotine if those fail (NG71, 1.5.2 to 1.5.7). More detail is in our guides to REM sleep behaviour disorder, restless legs syndrome, melatonin and sleep in neurological disease. For nighttime bathroom trips see nocturia.

Depression and anxiety

NICE refers clinicians to its depression guideline for people with a chronic physical health problem (NG71, 1.5.11). The SAD-PD trial randomised 115 people (paroxetine 42, venlafaxine XR 34, placebo 39). After 12 weeks HAM-D scores fell 6.2 points more than placebo with paroxetine (97.5% CI 2.2 to 10.3) and 4.2 points more with venlafaxine XR (0.1 to 8.4), without worsening motor function. Remission and 50% response rates did not differ significantly from placebo, 16% withdrew, venlafaxine raised sitting systolic blood pressure by 8.5 mm Hg, and the authors said the trial was too small to compare the two drugs (Richard et al. 2012). See major depressive disorder and depression in older adults. If mood drops, tell the Parkinson's team; do not stop a Parkinson's medicine to try to fix it.

Other non-motor problems NICE covers

NICE recommends reviewing medicines for orthostatic hypotension and considering midodrine, then fludrocortisone (NG71, 1.5.8 to 1.5.10); cholinesterase inhibitors for mild to moderate Parkinson's disease dementia (NG71, 1.5.22); quetiapine or, if that fails, clozapine for hallucinations and delusions that need treatment, and not olanzapine (NG71, 1.5.14 to 1.5.19); and glycopyrronium bromide for drooling once non-drug methods have been tried (NG71, 1.5.26 and 1.5.27).

Supplements and lifestyle claims, graded

We did not review observational claims about coffee, smoking, diet patterns or herbal products, because we did not open independent systematic reviews on them. Absence from this page does not mean they are safe or useless.

Risks and side effects

Interactions and who needs extra care

Medicines that can lower blood pressure on standing include antihypertensives, dopaminergic drugs, anticholinergics and antidepressants (NG71, 1.5.8). Women who are pregnant or planning a pregnancy should not take modafinil (NG71, 1.5.2). Quetiapine and clozapine need lower doses than in other conditions, and clozapine requires registration with a patient monitoring service (NG71, 1.5.17 and 1.5.18). Anyone admitted to hospital should have medicines given at the right times by or after discussion with a Parkinson's specialist (NG71, 1.3.4). We did not review food or supplement interactions beyond what NICE states, and we give no personal dosing advice.

Who to see

See a GP if you are concerned you may have symptoms; they may refer you to a specialist (NHS). NICE says people should be referred quickly, untreated, to a specialist with expertise in differential diagnosis, should have an accessible point of contact such as a Parkinson's disease nurse specialist, a comprehensive care plan, and regular access to clinical monitoring and medicine adjustment (NG71, 1.2.2, 1.1.5, 1.1.6 and 1.7.1). Carers have a right to a carer assessment (NG71, 1.1.4). NICE also advises offering opportunities to discuss prognosis, advance care planning and palliative care at any stage (NG71, 1.9.1 to 1.9.4).

Follow the money: who funds Parkinson's research

Who profits from the products

We did not trace brand owners or prices for individual Parkinson's medicines, and make no price claims. The clearest commercial link we documented is in deep brain stimulation: in the 2006 trial the electrode and pulse generator were Medtronic products, and many authors reported fees, grants or stock options from the firm (NEJM 2006). On the medicine side, the agonist impulse control study was sponsored by Boehringer Ingelheim (registry), and the antidepressant trial drugs were supplied by Wyeth and GlaxoSmithKline (SAD-PD).

Who funded the trials

• Public money: PD MED (UK NIHR and Department of Health), LEAP (Dutch ZonMw), the CoQ10 and creatine trials (NIH institutes) and SPARX (NIH) are all publicly or charity funded (PD MED; LEAP; QE3; NET-PD LS-1; SPARX). That helps independence but does not remove allegiance bias from researchers who want their hypothesis to succeed.
• Industry-supplied or sponsored: the antidepressant trial used drugs supplied by Wyeth and GlaxoSmithKline (SAD-PD). The impulse control study was sponsored by Boehringer Ingelheim (registry).
• Disease burden estimates: funded by the Gates Foundation, with some authors reporting grants from companies including Lundbeck (GBD full text).

The Michael J. Fox Foundation

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is a New York charity. ProPublica's Nonprofit Explorer, summarising its tax filings, lists revenue of $708,298,921, expenses of $607,173,235 and contributions of $689,453,611 for the year ending December 2025 (ProPublica). The foundation's own announcement of a $50 million challenge grant from Sergey Brin and Anne Wojcicki, matching new and increased gifts one-to-one through the end of 2012, is a documented example of a large private donor shaping research priorities, in that case its work on LRRK2 (MJFF, 31 May 2011). We state only the documented gift, not the donors' motives.

The foundation also works with industry. It describes the Parkinson's Progression Markers Initiative (PPMI) as sponsored and partially funded by MJFF, with other partners in industry, nonprofit and private funding, and the study's page shows companies such as AbbVie, Roche, Lilly, Lundbeck, Merck, Novartis and Sanofi among its partners (PPMI). Its partnerships page names companies including AbbVie, Genentech, Lilly, Merck, Roche and Takeda alongside nonprofits and says donations "do not influence" its content or panelist selection for its education programmes (MJFF partnerships). That is the foundation's statement of policy; it does not describe conflict-of-interest safeguards for research grants. The foundation also reported the negative exenatide result prominently (MJFF), which is a point in its favour.

Documented integrity events

• Paraquat litigation: more than 5,800 active suits in a US federal court by mid-April 2025; Syngenta, described by The New Lede as Chinese-owned, denies the claims and signed a letter agreement to settle many of them with undisclosed terms (The New Lede). The New Lede is an initiative of the Environmental Working Group, an advocacy organisation, so we treat it as tier 3 and use it only for the dates, counts and company statements.
• Exenatide-PD3 expression of concern: after a regulatory inspection at one trial site, The Lancet published an expression of concern on 27 June 2026 (PubMed lists it). The Limbic reports it followed an inspection at one trial site; we confirmed through PubMed that the notice exists (Lancet 2026;407:2588, 27 June 2026) but could not open its text or The Limbic, so the reason and outcome are unverified (The Limbic; Europe PMC record).

What this means: unlike many supplements, the core Parkinson's drug evidence is mostly publicly funded, and the supplement trials that disappointed were paid for by the US government. The biggest vulnerability is not a hidden seller; it is where a manufacturer supplies the hardware or drug (deep brain stimulation, antidepressant trial drugs), and where charity and industry money shape which questions get studied. When independent public trials, a government-funded guideline and a company-sponsored study all point the same way, as on agonists and impulse control, confidence is highest.

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• CoQ10: ubiquinone vs ubiquinol, heart health and statin muscle pain
• Creatine monohydrate: strength, cognition, safety and funding
• REM sleep behaviour disorder
• Restless legs syndrome
• Sleep and neurological disease
• Excessive daytime sleepiness
• Chronic constipation
• Major depressive disorder
• Depression in older adults
• Dysphagia (difficulty swallowing)
• Vitamin D
• Exercise and social support for mental health

Frequently asked questions

Sources and funding notes

What we could not verify: We re-read the live NICE NG71 recommendations page (published 19 July 2017; its history page lists no later update) and the section numbers cited match it. We did not open a NICE funding page and rely on the standard description of NICE as a UK public body paid through the Department of Health and Social Care. We could not open the full text of PD MED, LEAP or EARLYSTIM, so author conflict declarations for those trials are not recorded; their funding comes from PubMed abstract-level records, which we re-checked. We could not open the Cochrane review's funding statement (Cochrane's site blocked access). A search extract credited a German ministry grant; we did not confirm it. We could not confirm who supplied CoQ10 or creatine for the NIH trials. The Weintraub paper's own funding statement was not available, so the sponsor is from the trial registry. We read the Cereda and Pezzoli pesticide meta-analysis only through a press release. We could not open the Lancet's expression-of-concern notice for Exenatide-PD3, and we found no SPARX3 results. We did not verify costs, market sizes, brand owners for individual Parkinson's medicines, or the current legal status of paraquat in any country. We did not review the evidence on diet, coffee, smoking, herbal products, the newer apomorphine or gel infusion devices, or surgery other than DBS. Nothing here is a statement about any living person's motives.

1. NICE NG71. Parkinson's disease in adults (2017) — UK guideline; Department of Health and Social Care.
2. NHS. Parkinson's disease — UK government health information; last reviewed November 2022.
3. PD MED Collaborative Group. Lancet 2014 — open-label randomised trial; NIHR HTA programme and Department of Health.
4. Verschuur et al. NEJM 2019 (LEAP) — randomised delayed-start trial; ZonMw and Dutch patient charities.
5. Frequin et al. Movement Disorders 2024 — LEAP long-term follow-up; ZonMw and Dutch charities.
6. NIHR Evidence. When is it best to start levodopa? — plain-language summary; UK government funded.
7. Ernst et al. Cochrane 2023. Physical exercise for people with Parkinson's disease — network meta-analysis; funder not confirmed by us.
8. Cochrane news item on the exercise review, 13 January 2023 — summary by Cochrane.
9. Schenkman et al. JAMA Neurol 2018 (SPARX) and full text — phase 2 trial; NIH (NINDS) and Parkinson's Disease Foundation.
10. SPARX3 protocol — NINDS U01 grant; phase 3 trial design.
11. Beal et al. JAMA Neurol 2014 (QE3) and registry NCT00740714 — CoQ10 trial; NIH.
12. Kieburtz et al. JAMA 2015 (NET-PD LS-1) and registry NCT00449865 — creatine trial; NIH institutes.
13. Deuschl et al. NEJM 2006 — DBS trial; German ministry grant; Medtronic devices and author ties.
14. Schuepbach et al. NEJM 2013 (EARLYSTIM) — DBS trial; German Ministry of Research and others.
15. Richard et al. Neurology 2012 (SAD-PD) — antidepressant trial; NIH; drugs supplied by Wyeth and GlaxoSmithKline.
16. Weintraub et al. Arch Neurol 2010 and registry NCT00617019 — impulse control study; Boehringer Ingelheim as sponsor.
17. Tanner et al. Environ Health Perspect 2011 — pesticide case-control study; NIH intramural programme and private donors.
18. American Academy of Neurology press release on Cereda and Pezzoli (2013) — Italian foundations funded the meta-analysis.
19. The New Lede. Syngenta moving to settle lawsuits (April 2025) — advocacy-group journalism; used for litigation counts and company statements.
20. GBD 2016 Parkinson's Disease Collaborators. Lancet Neurol 2018 and full text — Gates Foundation.
21. Probiotics for constipation in Parkinson's: meta-analysis — Chinese authors; no funding statement found.
22. Vijiaratnam et al. Lancet 2025 (Exenatide-PD3) — NIHR and Cure Parkinson's; MJFF news item; The Limbic report on the expression of concern.
23. MJFF. Parkinson's inosine trial ending early — foundation news page; SURE-PD3.
24. ProPublica Nonprofit Explorer. Michael J Fox Foundation — tax filings; PPMI study sponsors; MJFF current partnerships; MJFF. Brin Wojcicki Foundation $50 million challenge.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.